CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
1.5168
4.41%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.0364
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026207 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026207%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003985 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003985%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Biodesix Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 1.5868
Open* 1.5968
1-Year Change* 21.17%
Day's Range* 1.5168 - 1.6168
52 wk Range 1.03-2.53
Average Volume (10 days) 29.33K
Average Volume (3 months) 1.48M
Market Cap 119.43M
P/E Ratio -100.00K
Shares Outstanding 90.48M
Revenue 44.03M
EPS -0.90
Dividend (Yield %) N/A
Beta -100.00K
Next Earnings Date Mar 4, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Dec 7, 2023 1.5868 0.0400 2.59% 1.5468 1.6168 1.4968
Dec 6, 2023 1.4868 0.0200 1.36% 1.4668 1.6168 1.4368
Dec 5, 2023 1.4868 0.0300 2.06% 1.4568 1.4968 1.4468
Dec 4, 2023 1.4768 0.0300 2.07% 1.4468 1.4868 1.4268
Dec 1, 2023 1.4468 -0.0600 -3.98% 1.5068 1.5168 1.3768
Nov 30, 2023 1.4568 0.0100 0.69% 1.4468 1.4868 1.4268
Nov 29, 2023 1.4868 -0.0100 -0.67% 1.4968 1.4968 1.4568
Nov 28, 2023 1.4768 0.0200 1.37% 1.4568 1.4768 1.4168
Nov 27, 2023 1.4568 -0.0300 -2.02% 1.4868 1.4868 1.4568
Nov 24, 2023 1.4868 0.0300 2.06% 1.4568 1.5068 1.4568
Nov 22, 2023 1.4268 0.0600 4.39% 1.3668 1.4868 1.3668
Nov 21, 2023 1.3168 -0.0700 -5.05% 1.3868 1.3968 1.2468
Nov 20, 2023 1.3968 -0.0200 -1.41% 1.4168 1.4268 1.3768
Nov 17, 2023 1.3868 -0.0500 -3.48% 1.4368 1.4468 1.3668
Nov 16, 2023 1.3968 0.0000 0.00% 1.3968 1.4168 1.3768
Nov 15, 2023 1.4268 0.1200 9.18% 1.3068 1.4268 1.3068
Nov 14, 2023 1.3268 0.0600 4.74% 1.2668 1.3268 1.2668
Nov 13, 2023 1.2568 -0.0400 -3.08% 1.2968 1.2968 1.2268
Nov 10, 2023 1.1968 -0.0400 -3.23% 1.2368 1.2468 1.1568
Nov 9, 2023 1.2368 -0.0600 -4.63% 1.2968 1.3268 1.2268

Biodesix, Inc. Events

Time (UTC) Country Event
Monday, March 4, 2024

Time (UTC)

13:30

Country

US

Event

Q4 2023 Biodesix Inc Earnings Release
Q4 2023 Biodesix Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 38.212 54.506 45.557 24.552 20.432
Revenue 38.212 54.506 45.557 24.552 20.432
Cost of Revenue, Total 14.154 30.518 21.998 6.074 4.406
Gross Profit 24.058 23.988 23.559 18.478 16.026
Total Operating Expense 95.78 93.148 68.491 51.293 44.095
Selling/General/Admin. Expenses, Total 58.458 47.958 32.328 30.637 25.899
Research & Development 13.102 12.789 10.818 10.468 8.188
Unusual Expense (Income) 7.062 -2.298 3.451 1.739
Other Operating Expenses, Total 0 1.622 0.818 0.663 3.863
Operating Income -57.568 -38.642 -22.934 -26.741 -23.663
Interest Income (Expense), Net Non-Operating -8.072 -4.508 -7.586 -2.953 -2.892
Other, Net 0.193 -0.009 -0.83 -1.032 0.389
Net Income Before Taxes -65.447 -43.159 -31.35 -30.726 -26.166
Net Income After Taxes -65.447 -43.159 -31.35 -30.726 -26.166
Net Income Before Extra. Items -65.447 -43.159 -31.35 -30.726 -26.166
Net Income -65.447 -43.159 -31.35 -30.726 -26.166
Income Available to Common Excl. Extra. Items -65.447 -43.159 -31.35 -30.726 -26.166
Income Available to Common Incl. Extra. Items -65.447 -43.159 -31.35 -30.726 -26.166
Diluted Net Income -65.447 -43.159 -31.35 -30.726 -26.166
Diluted Weighted Average Shares 42.103 27.365 26.5615 26.2541 26.2541
Diluted EPS Excluding Extraordinary Items -1.55445 -1.57716 -1.18028 -1.17033 -0.99665
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS -1.38672 -1.66114 -1.14948 -1.03889 -0.93041
Depreciation / Amortization 3.004 2.559 2.529
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 11.872 9.056 9.607 11.107 10.95
Revenue 11.872 9.056 9.607 11.107 10.95
Cost of Revenue, Total 3.238 3.169 3.306 3.633 3.98
Gross Profit 8.634 5.887 6.301 7.474 6.97
Total Operating Expense 22.799 25.429 27.474 21.769 25.528
Selling/General/Admin. Expenses, Total 16.651 18.989 16.626 15.114 15.235
Research & Development 2.91 3.251 3.565 2.97 3.361
Unusual Expense (Income) 0 0.02 3.977 0.052 2.952
Operating Income -10.927 -16.373 -17.867 -10.662 -14.578
Interest Income (Expense), Net Non-Operating -2.43 -2.391 -2.55 -3.039 -1.346
Other, Net 0.001 0.062 0.079 0.002 0.1
Net Income Before Taxes -13.356 -18.702 -20.338 -13.699 -15.824
Net Income After Taxes -13.356 -18.702 -20.338 -13.699 -15.824
Net Income Before Extra. Items -13.356 -18.702 -20.338 -13.699 -15.824
Net Income -13.356 -18.702 -20.338 -13.699 -15.824
Income Available to Common Excl. Extra. Items -13.356 -18.702 -20.338 -13.699 -15.824
Income Available to Common Incl. Extra. Items -13.356 -18.702 -20.338 -13.699 -15.824
Diluted Net Income -13.356 -18.702 -20.338 -13.699 -15.824
Diluted Weighted Average Shares 78.506 77.765 57.553 40.448 39.239
Diluted EPS Excluding Extraordinary Items -0.17013 -0.24049 -0.35338 -0.33868 -0.40327
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.17013 -0.24024 -0.28428 -0.3374 -0.32804
Other Operating Expenses, Total 0 0 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 53.334 43.613 86.14 12.7 9.913
Cash and Short Term Investments 43.088 32.712 62.126 5.286 5.914
Cash & Equivalents 43.088 32.712 62.126 5.286 5.914
Total Receivables, Net 5.065 3.656 15.304 5.292 1.892
Accounts Receivable - Trade, Net 5.065 3.656 15.304 5.292 1.892
Other Current Assets, Total 5.181 7.245 8.71 2.122 2.107
Total Assets 92.906 76.097 121.07 41.633 39.057
Property/Plant/Equipment, Total - Net 8.821 4.179 3.178 2.12 1.388
Property/Plant/Equipment, Total - Gross 15.839 10.928 9.902 8.506 6.956
Accumulated Depreciation, Total -7.018 -6.749 -6.724 -6.386 -5.568
Goodwill, Net 15.031 15.031 15.031 11.631 10.804
Intangibles, Net 9.797 11.617 13.26 15.092 16.852
Other Long Term Assets, Total 5.923 1.657 3.461 0.09 0.1
Total Current Liabilities 22.839 28.96 32.125 22.6 4.468
Accounts Payable 1.685 1.662 8.964 1.717 0.886
Accrued Expenses 7.446 4.899 4.69 1.899 1.568
Notes Payable/Short Term Debt 0 0 0 12.045 0
Other Current Liabilities, Total 13.659 22.38 6.631 6.939 2.014
Total Liabilities 72.3 56.37 79.904 76.213 53.125
Total Long Term Debt 25.004 9.993 15.926 23.812 23.099
Long Term Debt 25.004 9.993 15.926 23.812 23.099
Other Liabilities, Total 24.457 17.417 31.853 29.801 25.558
Total Equity 20.606 19.727 41.166 -34.58 -14.068
Redeemable Preferred Stock 0 0 0 193.959 183.962
Common Stock 0.078 0.031 0.027 0.001 0.001
Additional Paid-In Capital 387.948 321.669 299.953 2.324 2.107
Retained Earnings (Accumulated Deficit) -367.42 -301.973 -258.814 -230.864 -200.138
Total Liabilities & Shareholders’ Equity 92.906 76.097 121.07 41.633 39.057
Total Common Shares Outstanding 77.6144 30.7896 26.5615 26.2541 26.2541
Current Port. of LT Debt/Capital Leases 0.049 0.019 11.84 0
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 28.886 25.245 34.784 53.334 24.118
Cash and Short Term Investments 19.841 17.409 25.275 43.088 15.175
Cash & Equivalents 19.841 17.409 25.275 43.088 15.175
Total Receivables, Net 5.777 4.119 4.901 5.065 4.449
Accounts Receivable - Trade, Net 5.777 4.119 4.901 5.065 4.449
Other Current Assets, Total 3.268 3.717 4.608 5.181 4.494
Total Assets 86.786 77.623 80.793 92.906 63.198
Property/Plant/Equipment, Total - Net 27.488 21.488 15.291 8.821 7.734
Property/Plant/Equipment, Total - Gross 35.364 29.079 22.599 15.839 15.151
Accumulated Depreciation, Total -7.876 -7.591 -7.308 -7.018 -7.417
Goodwill, Net 15.031 15.031 15.031 15.031 15.031
Intangibles, Net 8.416 8.871 9.311 9.797 10.223
Other Long Term Assets, Total 6.965 6.988 6.376 5.923 6.092
Total Current Liabilities 32.649 27.951 22.098 22.839 37.415
Accounts Payable 2.904 3.501 1.563 1.685 2.1
Accrued Expenses 5.68 6.687 6.027 7.446 6.017
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 0.05 0.05 0.05 0.049 14.334
Other Current Liabilities, Total 24.015 17.713 14.458 13.659 14.964
Total Liabilities 88.232 84.616 76.243 72.3 66.101
Total Long Term Debt 24.95 24.658 25.084 25.004 4.88
Long Term Debt 24.95 24.658 25.084 25.004 4.88
Other Liabilities, Total 30.633 32.007 29.061 24.457 23.806
Total Equity -1.446 -6.993 4.55 20.606 -2.903
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.088 0.079 0.078 0.078 0.041
Additional Paid-In Capital 408.893 392.406 390.594 387.948 344.138
Retained Earnings (Accumulated Deficit) -410.427 -399.478 -386.122 -367.42 -347.082
Total Liabilities & Shareholders’ Equity 86.786 77.623 80.793 92.906 63.198
Total Common Shares Outstanding 88.3158 78.6107 77.9794 77.6144 41.1855
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -65.447 -43.159 -31.35 -30.726 -26.166
Cash From Operating Activities -44.972 -28.223 -21.366 -21.726 -17.677
Cash From Operating Activities 3.597 3.178 2.903 2.793 1.74
Non-Cash Items 20.316 7.167 11.882 7.852 6.496
Changes in Working Capital -3.438 4.591 -4.801 -1.645 0.253
Cash From Investing Activities -3.534 -2.547 -2.927 -1.872 -0.617
Capital Expenditures -3.534 -2.547 -2.177 -1.416 -0.617
Other Investing Cash Flow Items, Total 0 -0.75 -0.456 0
Cash From Financing Activities 58.882 1.262 81.131 22.972 19.032
Financing Cash Flow Items -17.423 -0.5 -8.249 -0.119 -0.283
Issuance (Retirement) of Stock, Net 59.807 17.112 73.34 10.047 8.55
Issuance (Retirement) of Debt, Net 16.498 -15.35 16.04 13.044 10.765
Net Change in Cash 10.376 -29.508 56.838 -0.626 0.738
Cash Interest Paid 1.009 1.676 1.844
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -18.702 -65.447 -45.109 -31.41 -15.586
Cash From Operating Activities -7.686 -44.972 -33.024 -22.693 -13.099
Cash From Operating Activities 0.785 3.597 2.699 1.806 0.908
Non-Cash Items 4.555 20.316 13.452 8.61 2.674
Changes in Working Capital 5.676 -3.438 -4.066 -1.699 -1.095
Cash From Investing Activities -7.706 -3.534 -1.547 -0.732 -0.352
Capital Expenditures -7.706 -3.534 -1.547 -0.732 -0.352
Other Investing Cash Flow Items, Total
Cash From Financing Activities -2.421 58.882 17.034 19.299 -2.834
Financing Cash Flow Items -2.415 -17.423 -11.145 -9.005 -4.6
Issuance (Retirement) of Stock, Net 0.006 59.807 18.115 16.227 1.674
Issuance (Retirement) of Debt, Net -0.012 16.498 10.064 12.077 0.092
Net Change in Cash -17.813 10.376 -17.537 -4.126 -16.285
Cash Interest Paid 1.032 1.009 0.473 0.344 0.223
Cash Taxes Paid 0 0 0
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Schuler (Jack W) Individual Investor 38.8981 30579359 10190170 2023-08-03 LOW
Kennedy (Lawrence T Jr.) Individual Investor 26.7131 21000243 6172839 2023-08-03 LOW
Patience (John) Individual Investor 9.3219 7328336 308641 2023-08-03 LOW
Birchview Capital, LP Investment Advisor 6.4106 5039633 0 2023-06-30 LOW
AIGH Capital Management, LLC. Private Equity 4.8311 3797936 -386403 2023-06-30 MED
Cawthorn (Robert E) Individual Investor 4.6458 3652220 1723341 2022-11-21
Strobeck (Matthew W) Individual Investor 3.8574 3032445 127777 2023-08-03
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 1.644 1292439 61597 2023-06-30 LOW
Worth Venture Partners, LLC Investment Advisor/Hedge Fund 1.6072 1263491 -96701 2023-06-30 HIGH
Essex Investment Management Company, LLC Investment Advisor/Hedge Fund 1.313 1032213 246561 2023-06-30 LOW
Wells Fargo Advisors Research Firm 1.0712 842138 40197 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 0.5152 405042 9397 2023-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.4701 369552 134585 2023-06-30 LOW
Legato Capital Management LLC Investment Advisor 0.4253 334310 -19647 2023-09-30 HIGH
Hutton Scott Individual Investor 0.4045 318013 77291 2023-08-10 MED
Massarany (Hany) Individual Investor 0.38 298707 160773 2023-03-31 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.3503 275350 251300 2023-06-30 LOW
Watts (Charles McDonald) Individual Investor 0.2979 234166 12345 2023-08-03
Bridgeway Capital Management, LLC Investment Advisor 0.2926 230000 50600 2023-06-30 MED
Cannell & Co. Investment Advisor 0.2615 205605 0 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Biodesix, Inc. Company profile

About Biodesix Inc

Biodesix, Inc. is a United States-based company engaged in developing and commercializing blood-based diagnostic tests for oncology. The Company’s product Biodesix Lung Reflex integrates genomic and proteomic blood-based results to reveal both sides of lung cancer. Its GeneStrat test offers blood-based mutation results within 72 hours for patients with non-small cell lung cancer (NSCLC). Its VeriStrat testing provides blood-based predictive and prognostic proteomic information with (NSCLC) who test negative for estimated glomerular filtration rate (EGFR) mutations (EGFR wild-type) or whose EGFR mutation status is unknown.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Biodesix Inc revenues increased 20% to $54.5M. Net loss increased 38% to $43.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Sales, marketing, general and administ increase of 49% to $43.6M (expense), Research and development - Balancing v increase of 19% to $12.2M (expense).

Industry: Medical & Diagnostic Laboratories

Suite 100
2970 Wilderness Place
BOULDER
COLORADO 80301
US

Income Statement

  • Annual
  • Quarterly

News

December RBA preview: no move expected at the final meeting of 2023

The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

14:47, 4 December 2023

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

12:39, 30 November 2023

Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

EZ PI expected to drop further but speed of decline

08:16, 29 November 2023

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023

People also watch

BTC/USD

43,825.85 Price
+1.120% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

XRP/USD

0.67 Price
+1.460% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

Oil - Crude

71.28 Price
+2.470% 1D Chg, %
Long position overnight fee -0.0204%
Short position overnight fee -0.0015%
Overnight fee time 22:00 (UTC)
Spread 0.030

US100

16,097.40 Price
+0.340% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading